Institut Curie, Stress and Cancer Laboratory, Equipe labelisée Ligue Nationale Contre le Cancer, PSL Research University, Paris, France.
U830, Inserm, Paris, France.
Immunol Rev. 2021 Jul;302(1):259-272. doi: 10.1111/imr.12978. Epub 2021 May 19.
The tumor microenvironment (TME) has been identified as one of the driving factors of tumor progression and invasion. Within this microenvironment, cancer-associated fibroblasts (CAF) have multiple tumor-promoting functions and play key roles in drug resistance, through multiple mechanisms, including extracellular matrix (ECM) remodeling, production of growth factors, cytokines, and chemokines, and modulation of metabolism and angiogenesis. More recently, a growing body of evidence has shown that CAF also modulate immune cell activity and suppress anti-tumor immune response. In this review, we describe the current knowledge on CAF heterogeneity in terms of identity and functions. Moreover, we analyze how distinct CAF subpopulations differentially interact with immune cells, with a particular focus on T lymphocytes. We address how specific CAF subsets contribute to cancer progression through induction of an immunosuppressive microenvironment. Finally, we highlight potential therapeutic strategies for targeting CAF subpopulations in cancer.
肿瘤微环境(TME)已被确定为肿瘤进展和侵袭的驱动因素之一。在这个微环境中,癌症相关成纤维细胞(CAF)具有多种促进肿瘤的功能,并通过多种机制在耐药性中发挥关键作用,包括细胞外基质(ECM)重塑、生长因子、细胞因子和趋化因子的产生以及代谢和血管生成的调节。最近,越来越多的证据表明,CAF 还调节免疫细胞活性并抑制抗肿瘤免疫反应。在这篇综述中,我们根据身份和功能描述了 CAF 异质性的最新知识。此外,我们分析了不同的 CAF 亚群如何与免疫细胞不同地相互作用,特别关注 T 淋巴细胞。我们讨论了特定的 CAF 亚群如何通过诱导免疫抑制微环境促进癌症进展。最后,我们强调了针对癌症中 CAF 亚群的潜在治疗策略。
Front Immunol. 2025-7-16
Signal Transduct Target Ther. 2025-7-31
Cancers (Basel). 2021-1-22
J Immunol. 2021-1-15
Proc Natl Acad Sci U S A. 2020-11-17
Oncotarget. 2020-10-6
Breast Cancer Res. 2020-7-14